ReviewCold Spring Harbor perspectives in medicine2015
Hepatocellular carcinoma.
Review in Cold Spring Harbor perspectives in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 93 citations in OpenAlex.
- Assessment of the diagnostic performance and influencing factors of AFP and PIVKA-II in hepatocellular carcinoma.Discover oncology · 2026Article
- Plant-Derived Secondary Metabolites Modulating Inflammation-Driven Pathways in Hepatocellular Carcinoma: Preclinical Insights.Current issues in molecular biology · 2026Review
- Review
- Probability analysis of hepatocellular carcinoma in hepatitis patients in the gray zone.Frontiers in medicine · 2024Article
- Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC).ESMO gastrointestinal oncology · 2023Review
- Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection.Clinical and molecular hepatology · 2023Review
- C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancerOncology letters · 2022Article
- Review
- Immunobiology and pathogenesis of hepatitis B virus infection.Nature reviews. Immunology · 2022Review
- Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application.Frontiers in oncology · 2022Review
- NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis.Oncology letters · 2021Article
- Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation.Viruses · 2021Review
- Review
- A CpG Methylation Signature as a Potential Marker for Early Diagnosis of Hepatocellular Carcinoma From HBV-Related Liver Disease Using Multiplex Bisulfite Sequencing.Frontiers in oncology · 2021Article
- Hepatocellular carcinoma: old friends and new tricks.Experimental & molecular medicine · 2020Review
- Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation.Hepatology international · 2020Article
- Transarterial Chemoembolization in a Woodchuck Model of Hepatocellular Carcinoma.Journal of vascular and interventional radiology : JVIR · 2020Article
- In Vitro Anti-hepatoma Activities of Notoginsenoside R1 Through Downregulation of Tumor Promoter miR-21.Digestive diseases and sciences · 2020Article
- Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-κB signaling pathway in liver cancer.Oncology letters · 2020Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hepatitis B virus (HBV) is a widespread human pathogen that causes liver inflammation, cirrhosis, and hepatocellular carcinoma (HCC). Recent sequencing technologies have refined our knowledge of the genomic landscape and pathogenesis of HCC, but the mechanisms by which HBV exerts its oncogenic role remain controversial. In a prevailing view, inflammation, liver damage, and regeneration may foster the accumulation of genetic and epigenetic defects leading to cancer onset. However, a more direct and specific contribution of the virus is supported by clinical and biological observations. Among genetically heterogeneous HCCs, HBV-related tumors display high genomic instability, which may be attributed to the ability of HBV to integrate its DNA into the host cell genome, provoking chromosomal alterations and insertional mutagenesis of cancer genes. The viral transactivator HBx may also participate in transformation by deregulating diverse cellular machineries. A better understanding of the complex mechanisms linking HBV to HCC will improve prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.